Latest Leadership And Governance News

Seven West Media and Southern Cross Media have announced a proposed all-scrip merger to create a leading integrated media company spanning TV, audio, digital, and publishing platforms across Australia.

Seven West Media and Southern Cross Media have agreed to merge, creating a dominant integrated media company with extensive reach across TV, audio, and digital platforms in Australia. The merger promises significant cost synergies and enhanced shareholder value, pending regulatory and shareholder approvals.

Metal Bank Limited has agreed to acquire Hastings Technology Metals’ Western Australian gold assets, expanding its portfolio and advancing key projects toward production.

My Foodie Box Limited is set to pivot from meal kits to mining by acquiring Australian gold, copper, and rare earth projects, renaming itself Tarrina Resources, and relisting on the ASX with a $5 million capital raise.

Botanix Pharmaceuticals posted a sharp revenue increase driven by its new hyperhidrosis treatment Sofdra, yet reported a substantial net loss reflecting heavy investment in commercialisation. The company’s strong cash position underpins its path to profitability.

Clime Investment Management Limited has reported a significant turnaround in FY25, returning to profitability with a 13% revenue increase and proposing a fully franked final dividend. The company expanded its business lines and strengthened its leadership team, setting a positive outlook for FY26.

Chimeric Therapeutics reported a reduced net loss of $10.43 million for FY2025, driven by cost efficiencies and strategic project reprioritisation, while making significant clinical progress in its CAR T-cell and NK cell therapy programs.

Firebrick Pharma reported a substantial increase in Nasodine Nasal Spray revenues in FY25, alongside a widening net loss driven by reduced R&D incentives and increased marketing investments. The company is advancing its international rollout with new licensing deals and board appointments.

Orthocell Ltd reported a record $9.23 million revenue for FY25, driven by strong sales of its nerve repair and dental products, alongside securing US FDA clearance for its flagship nerve repair device Remplir. The company is poised for accelerated growth as it expands its global commercial footprint.

Tissue Repair Ltd reported a 27.3% revenue increase to $3.22 million for FY25, driven by new distribution deals and regulatory progress, while continuing to invest heavily in clinical trials and manufacturing scale-up, resulting in a $4.24 million loss.

Atomo Diagnostics reported a 27% reduction in net loss to AUD 4.97 million for FY25, alongside a 7% revenue dip to AUD 3.79 million, driven by stronger margins and cost controls. The company also secured a significant US distribution contract through partner Lumos Diagnostics, positioning it for growth.

Acrux Ltd reported a 44% revenue decline and a modest increase in net loss for FY25, while expanding its US topical generics portfolio and entering the Saudi Arabian market. The company signals a strategic pivot amid intensifying competition and lower returns.